Herbert Tilg

893 total citations
13 papers, 599 citations indexed

About

Herbert Tilg is a scholar working on Epidemiology, Genetics and Surgery. According to data from OpenAlex, Herbert Tilg has authored 13 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 4 papers in Genetics and 2 papers in Surgery. Recurrent topics in Herbert Tilg's work include Liver Disease Diagnosis and Treatment (4 papers), Inflammatory Bowel Disease (4 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Herbert Tilg is often cited by papers focused on Liver Disease Diagnosis and Treatment (4 papers), Inflammatory Bowel Disease (4 papers) and Adipokines, Inflammation, and Metabolic Diseases (3 papers). Herbert Tilg collaborates with scholars based in Austria, Italy and United States. Herbert Tilg's co-authors include Alexander R. Moschen, Verena Wieser, Arthur Kaser, Susanne Kaser, I Graziadei, Clemens Molnar, Sabine Geiger, Christoph Ebenbichler, Romana R. Gerner and Dietmar Fuchs and has published in prestigious journals such as JAMA, Gastroenterology and Gut.

In The Last Decade

Herbert Tilg

12 papers receiving 587 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Herbert Tilg Austria 8 331 156 143 93 83 13 599
Hongliang Xue China 12 193 0.6× 253 1.6× 381 2.7× 51 0.5× 105 1.3× 19 698
Jeanne Walker United States 8 216 0.7× 359 2.3× 428 3.0× 74 0.8× 86 1.0× 12 871
Mirjam H. Koster Netherlands 9 94 0.3× 134 0.9× 283 2.0× 116 1.2× 37 0.4× 21 515
Daphne Dekker Netherlands 9 112 0.3× 131 0.8× 307 2.1× 78 0.8× 35 0.4× 12 527
Laurent L’homme Belgium 10 283 0.9× 180 1.2× 338 2.4× 82 0.9× 67 0.8× 14 688
Noemi Baffy United States 9 172 0.5× 149 1.0× 139 1.0× 81 0.9× 27 0.3× 14 567
Theodora Tzanavari Greece 7 249 0.8× 235 1.5× 148 1.0× 40 0.4× 55 0.7× 10 576
C.L. Sia United States 6 213 0.6× 224 1.4× 184 1.3× 54 0.6× 79 1.0× 6 616
Jennifer Tabita‐Martinez United States 6 286 0.9× 223 1.4× 213 1.5× 115 1.2× 112 1.3× 6 651
Hugo Villamil‐Ramírez Mexico 17 219 0.7× 216 1.4× 325 2.3× 85 0.9× 116 1.4× 26 687

Countries citing papers authored by Herbert Tilg

Since Specialization
Citations

This map shows the geographic impact of Herbert Tilg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herbert Tilg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herbert Tilg more than expected).

Fields of papers citing papers by Herbert Tilg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herbert Tilg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herbert Tilg. The network helps show where Herbert Tilg may publish in the future.

Co-authorship network of co-authors of Herbert Tilg

This figure shows the co-authorship network connecting the top 25 collaborators of Herbert Tilg. A scholar is included among the top collaborators of Herbert Tilg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herbert Tilg. Herbert Tilg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Vermeire, Séverine, Josianne Nitcheu, Paul Gineste, et al.. (2025). Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study. Journal of Crohn s and Colitis. 19(5). 1 indexed citations
2.
3.
Tilg, Herbert, et al.. (2025). Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults. JAMA. 335(2). 163–163. 2 indexed citations
4.
Pennisi, Grazia, Ciro Celsa, Marco Enea, et al.. (2024). Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies. Liver International. 44(11). 2939–2949. 12 indexed citations
5.
Feng, Gong, Yu Han, Wah Yang, et al.. (2024). Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery. Trends in Endocrinology and Metabolism. 36(2). 118–132. 11 indexed citations
6.
Adolph, Timon E., Verena Wieser, Christoph Grander, et al.. (2017). Adipose type I interferon signalling protects against metabolic dysfunction. Journal of Hepatology. 66(1). S609–S609. 23 indexed citations
7.
Gerner, Romana R., Verena Wieser, Alexander R. Moschen, & Herbert Tilg. (2013). Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Canadian Journal of Physiology and Pharmacology. 91(11). 867–872. 56 indexed citations
8.
Moschen, Alexander R., Verena Wieser, & Herbert Tilg. (2012). Adiponectin: Key Player in the Adipose Tissue-Liver Crosstalk. Current Medicinal Chemistry. 19(32). 5467–5473. 74 indexed citations
9.
Moschen, Alexander R., Clemens Molnar, Sabine Geiger, et al.. (2010). Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression. Gut. 59(9). 1259–1264. 211 indexed citations
10.
Moschen, Alexander R., et al.. (2007). P189 VISFATIN - A NOVEL MEMBER OF THE ADIPOCYTOKINE FAMILY IS ACTIVATED IN INFLAMMATORY BOWEL DISEASE. 1(1). 52–52. 1 indexed citations
11.
Reinisch, Walter, et al.. (2004). Immunsuppressiva in der Therapie chronisch entzündlicher Darmerkrankungen. Zeitschrift für Gastroenterologie. 42(9). 1033–1045. 4 indexed citations
12.
Wolf, Anna, Dominik Wolf‎, Holger Rumpold, et al.. (2004). Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clinical Immunology. 113(1). 47–55. 134 indexed citations
13.
Tilg, Herbert, Harald Vogelsang, Othmar Ludwiczek, et al.. (2003). A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis. Gastroenterology. 124(4). A62–A62. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hongliang Xue Breakdown of academic impact, for papers by Jeanne Walker Breakdown of academic impact, for papers by Mirjam H. Koster Breakdown of academic impact, for papers by Daphne Dekker Breakdown of academic impact, for papers by Laurent L’homme Breakdown of academic impact, for papers by Noemi Baffy Breakdown of academic impact, for papers by Theodora Tzanavari Breakdown of academic impact, for papers by C.L. Sia Breakdown of academic impact, for papers by Jennifer Tabita‐Martinez Breakdown of academic impact, for papers by Hugo Villamil‐Ramírez
Rankless by CCL
2026